Genaera to Present at BIO InvestorForum

PLYMOUTH MEETING, Pa., Oct. 23 /PRNewswire-FirstCall/ -- Genaera Corporation
(Nasdaq: GENR) will present at the 2008 BIO InvestorForum being held October
29-31 at the Palace Hotel in San Francisco, CA.Jack Armstrong, president and
chief executive officer, will present a company overview on Wednesday, October
29, 2008 at 2:15 p.m. (PST).

About Genaera
Genaera Corporation is developing trodusquemine (MSI-1436) for type 2 diabetes
and obesity currently in phase 1 clinical testing and has a fully out-licensed
partnership with MedImmune, Inc. that is in phase 2 clinical testing in
asthma. For further information, please see our website at
http://www.genaera.com.

This announcement contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 that are subject to risks
and uncertainties, known and unknown. Forward-looking statements reflect
management's current views and are based on certain expectations and
assumptions. You may identify some of these forward-looking statements by the
use of words in the statements such as "anticipate," "believe," "continue,"
"develop," "expect," "plan" and "potential" or other words of similar meaning.
Genaera's actual results and performance could differ materially from those
currently anticipated and expressed in these and other forward-looking
statements as a result of a number of risk factors, including, but not limited
to the risks and uncertainties discussed in Genaera's filings with the U.S.
Securities and Exchange Commission, all of which are available from the
Commission in its EDGAR database at www.sec.gov as well as other sources. You
are encouraged to read these reports. Given the uncertainties affecting
development stage pharmaceutical companies, you are cautioned not to place
undue reliance on any such forward-looking statements, any of which may turn
out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or
other factors. Genaera does not intend (and it is not obligated) to publicly
update, revise or correct these forward-looking statements or the risk factors
that may relate thereto.

SOURCE Genaera Corporation

Investor Relations: Genaera Corporation, +1-610-941-5675; or Media: Shirley
Chow of Porter Novelli Life Sciences, +1-212-601-8308,
schow@pnlifesciences.com